A phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant therapy for Participants with Resectable IIB or IIIA non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)